Soho Holly Corporation (600128.SH) plans to sell no more than 4.4 million A-shares of Soho Holly Futures.
Soho Holly Corporation (600128.SH) announced that, after approval by the shareholders' meeting and within three months from the expiration of the pre-disclosure period, the company plans to sell, through the Shenzhen Stock Exchange trading system by way of centralized bidding as opportunities arise, no more than 4.4 million A-shares of Soho Holly Futures (stock code 001236), with an estimated transaction amount of approximately RMB 34.76 million. This transaction will help the company recover funds and further focus on the development of its main business. The impact of this transaction on the company's current-period profit or loss is expected to exceed 50% of the company's net profit as audited for the most recent period.
Soho Holly Corporation (600128.SH) announced that, after approval by the shareholders' meeting and within three months from the expiry of the pre-disclosure period, the company plans to sell, through the Shenzhen Stock Exchange trading system by way of centralized bidding, no more than 4.4 million A-shares of Soho Holly Futures (stock code 001236) at an opportune time, with an estimated transaction amount of approximately RMB 34.76 million. This transaction will help the company recover funds and further focus on the development of its main business. The impact of this transaction on the company's current-period profit or loss is expected to exceed 50% of the company's net profit audited for the most recent period.
Related Articles
SF INTRA-CITY (09699) repurchased 231,400 shares for HK$2.0081 million on October 9.
PROSPEROUSPRINT (08385): Cheng Chi Sum Appointed as Independent Non-Executive Director
Jiangsu Gdk Biological Technology (688670.SH): Trivalent influenza vaccine receives drug registration certificate; the company may trigger a financial delisting risk warning.
SF INTRA-CITY (09699) repurchased 231,400 shares for HK$2.0081 million on October 9.
PROSPEROUSPRINT (08385): Cheng Chi Sum Appointed as Independent Non-Executive Director
Jiangsu Gdk Biological Technology (688670.SH): Trivalent influenza vaccine receives drug registration certificate; the company may trigger a financial delisting risk warning.
